Sign in

    Roanna Ruiz

    Research Analyst at Leerink

    Roanna Ruiz is the Senior Managing Director and Senior Biotechnology Analyst at Leerink Partners, specializing in biopharma with a particular focus on cardiovascular, endocrine disorders, and infectious disease companies such as Xeris Biopharma, Akebia Therapeutics, CorMedix, Lexicon Pharmaceuticals, and Vir Biotechnology. She is recognized for delivering deep-dive research and precise investment recommendations, with her analyst performance closely tracked across financial platforms, though specific ROI metrics are not publicly available. With a career starting in pharmaceutical consulting at IQVIA, she progressed through equity research roles at UBS and H.C. Wainwright before joining Leerink Partners in 2018 and rising through roles to Senior Managing Director in 2023. Holding a Ph.D. in Biomedical Engineering from Cornell University and a B.S. from Harvard, Ruiz is known for her science-driven approach and analytical rigor in biotechnology investment research.

    Roanna Ruiz's questions to LEXICON PHARMACEUTICALS (LXRX) leadership

    Roanna Ruiz's questions to LEXICON PHARMACEUTICALS (LXRX) leadership • Q4 2024

    Question

    Asked about the commercialization and partnership strategy for sotagliflozin in HCM across different regions and about baseline therapy requirements for the SONATA trial.

    Answer

    Viatris holds the license for sotagliflozin ex-U.S. and ex-Europe. Lexicon would seek a partner for Europe. For the U.S., Lexicon feels it has the capability to commercialize for HCM itself, noting a more favorable payer environment than for heart failure, but is open to partnerships. For the SONATA trial, there are no limitations on background therapy (including CMIs); the main inclusion criterion is that patients remain symptomatic with a low KCCQ score.

    Ask Fintool Equity Research AI

    Roanna Ruiz's questions to LEXICON PHARMACEUTICALS (LXRX) leadership • Q3 2024

    Question

    Asked about the rationale behind the Viatris partnership for sotagliflozin, the company's strategy for prioritizing future partnerships for its pipeline assets, and the potential positioning and differentiating features of LX9851 in the obesity treatment landscape.

    Answer

    The Viatris deal was driven by the need for a strong global partner with cardiometabolic expertise to commercialize sotagliflozin outside the US/EU. Partnering for LX9211 and LX9851 is a key focus. LX9851 is positioned as a differentiated oral small molecule with a novel mechanism that could be used in combination, preserve lean body mass, and serve as a maintenance therapy, complementing existing GLP-1 treatments.

    Ask Fintool Equity Research AI

    Roanna Ruiz's questions to ENANTA PHARMACEUTICALS (ENTA) leadership

    Roanna Ruiz's questions to ENANTA PHARMACEUTICALS (ENTA) leadership • Q1 2024

    Question

    Inquired about the rationale for choosing the Chronic Spontaneous Urticaria (CSU) indication, the optimization process for the candidate molecule, and the efficacy/safety expectations for the upcoming RSVPEDs data that would support advancing to Phase 3.

    Answer

    The company is optimizing its CSU candidate for potency, selectivity, and PK. They chose CSU based on a rigorous process and are exploring other immunology targets. For RSVPEDs, they are looking for positive directional trends in virology to support a move to Phase 3, given the study's small size.

    Ask Fintool Equity Research AI